{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:41:32Z","timestamp":1786977692186,"version":"build-2736575974"},"reference-count":107,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Depress Anxiety"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1002\/da.22680","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T16:13:52Z","timestamp":1504800832000},"page":"1134-1146","source":"Crossref","is-referenced-by-count":22,"title":["Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants"],"prefix":"10.1155","volume":"34","author":[{"given":"Chad","family":"Beyer","sequence":"first","affiliation":[{"name":"Department of Psychiatry; Stellenbosch University; Stellenbosch Western Cape South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiley","family":"Cappetta","sequence":"additional","affiliation":[{"name":"Barnard College; NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Child Study Centre; Yale University School of Medicine; New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-4080","authenticated-orcid":false,"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Yale University; New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"issue":"1","key":"10.1002\/da.22680-BIB0001|da22680-cit-0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.179.1.15","article-title":"Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study","volume":"179","author":"Allgulander","year":"2001","journal-title":"The British Journal of Psychiatry"},{"issue":"9","key":"10.1002\/da.22680-BIB0002|da22680-cit-0002","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","article-title":"Efficacy of sertraline in a 12-week trial for generalized anxiety disorder","volume":"161","author":"Allgulander","year":"2004","journal-title":"The American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/da.22680-BIB0003|da22680-cit-0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","article-title":"Efficacy of Venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine","volume":"19","author":"Allgulander","year":"2004","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"5","key":"10.1002\/da.22680-BIB0004|da22680-cit-0004","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1176\/appi.ajp.159.5.874-a","article-title":"Cyproheptadine for drug-induced sweating","volume":"159","author":"Ashton","year":"2002","journal-title":"The American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/da.22680-BIB0005|da22680-cit-0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia\/social anxiety disorder. Randomised, double- blind, placebo-controlled study. Paroxetine Study Group","volume":"175","author":"Baldwin","year":"1999","journal-title":"The British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/da.22680-BIB0006|da22680-cit-0006","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo-controlled, double-blind study","volume":"189","author":"Baldwin","year":"2006","journal-title":"The British Journal of Psychiatry"},{"key":"10.1002\/da.22680-BIB0007|da22680-cit-0007","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/7854_2009_2","article-title":"Pharmacological treatment of generalized anxiety disorder","volume":"2","author":"Baldwin","year":"2010","journal-title":"Current Topics on Behavioral Neurosciences"},{"issue":"7","key":"10.1002\/da.22680-BIB0008|da22680-cit-0008","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/da.22680-BIB0009|da22680-cit-0009","volume-title":"Comprehensive meta-analysis","author":"Biostat","year":"2015"},{"key":"10.1002\/da.22680-BIB0035|da22680-cit-0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bjp.174.4.297","article-title":"Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials","volume":"174","author":"Bollini","year":"1999","journal-title":"The British Journal of Psychiatry: The Journal of Mental Science"},{"issue":"10","key":"10.1002\/da.22680-BIB0010|da22680-cit-0010","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/da.20355","article-title":"Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder","volume":"25","author":"Bose","year":"2008","journal-title":"Depression and Anxiety"},{"issue":"3","key":"10.1002\/da.22680-BIB0011|da22680-cit-0011","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day","volume":"29","author":"Boulenger","year":"2014","journal-title":"International Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/da.22680-BIB0012|da22680-cit-0012","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1002\/da.22680-BIB0013|da22680-cit-0013","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1192\/bjp.187.4.352","article-title":"Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study","volume":"187","author":"Bradwejn","year":"2005","journal-title":"The British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/da.22680-BIB0014|da22680-cit-0014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200831020-00002","article-title":"Drug-induced hyperhidrosis and hypohidrosis: Incidence, prevention and management","volume":"31","author":"Cheshire","year":"2008","journal-title":"Drug Safety"},{"key":"10.1002\/da.22680-BIB0015|da22680-cit-0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-199210002-00007","article-title":"Sertraline in the treatment of obsessive compulsive disorder","volume":"7","author":"Chouinard","year":"1992","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/da.22680-BIB0016|da22680-cit-0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004714-199604000-00003","article-title":"Fluvoxamine maleate in the treatment of depression","volume":"16","author":"Claghorn","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/da.22680-BIB0017|da22680-cit-0017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/da.20695","article-title":"Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder","volume":"27","author":"Coric","year":"2010","journal-title":"Depression and Anxiety"},{"issue":"4","key":"10.1002\/da.22680-BIB0018|da22680-cit-0018","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4088\/JCP.v67n0411","article-title":"Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review","volume":"67","author":"Dell'Osso","year":"2006","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/da.22680-BIB0019|da22680-cit-0019","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","article-title":"Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial","volume":"14","author":"Detke","year":"2004","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/da.22680-BIB0020|da22680-cit-0020","first-page":"84","article-title":"A double-blind placebo-controlled study of fluvoxamine and imipramine in depression","volume":"46","author":"Dominguez","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7061","key":"10.1002\/da.22680-BIB0021|da22680-cit-0021","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/bmj.313.7061.861","article-title":"Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5","volume":"313","author":"Donoghue","year":"1996","journal-title":"Bmj"},{"issue":"3","key":"10.1002\/da.22680-BIB0022|da22680-cit-0022","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1192\/bjp.159.3.394","article-title":"A comparison of paroxetine, imipramine and placebo in depressed out- patients","volume":"159","author":"Dunbar","year":"1991","journal-title":"The British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/da.22680-BIB0023|da22680-cit-0023","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0b013e31822c0a68","article-title":"Symptomatic and functional improvement in employed depressed patients","volume":"31","author":"Dunlop","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/da.22680-BIB0024|da22680-cit-0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/hup.470080306","article-title":"Placebo-controlled trial of paroxetine in depressive illness","volume":"8","author":"Edwards","year":"1993","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"2","key":"10.1002\/da.22680-BIB0025|da22680-cit-0025","first-page":"119","article-title":"Fluvoxamine versus imipramine and placebo: A double-blind comparison in depressed patients","volume":"11","author":"Fabre","year":"1996","journal-title":"International Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/da.22680-BIB0026|da22680-cit-0026","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/0006-3223(95)00178-8","article-title":"Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo","volume":"38","author":"Fabre","year":"1995","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/da.22680-BIB0027|da22680-cit-0027","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-198907000-00006","article-title":"A Placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression","volume":"4","author":"Feighner","year":"1989","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/da.22680-BIB0028|da22680-cit-0028","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0165-0327(93)90035-I","article-title":"A study comparing paroxetine placebo and imipramine in depressed patients","volume":"28","author":"Feighner","year":"1993","journal-title":"Journal of Affective Disorders"},{"issue":"10","key":"10.1002\/da.22680-BIB0029|da22680-cit-0029","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/03007995.2011.609540","article-title":"Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: A replication study","volume":"27","author":"Gaynor","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"10","key":"10.1002\/da.22680-BIB0030|da22680-cit-0030","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1185\/03007995.2011.609539","article-title":"A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms","volume":"27","author":"Gaynor","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"23","key":"10.1002\/da.22680-BIB0031|da22680-cit-0031","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","article-title":"Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder","volume":"283","author":"Gelenberg","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/da.22680-BIB0032|da22680-cit-0032","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/13651501.2012.687449","article-title":"Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: A randomized controlled trial","volume":"17","author":"Ghaleiha","year":"2013","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"7","key":"10.1002\/da.22680-BIB0033|da22680-cit-0033","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4088\/JCP.v63n0707","article-title":"Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression","volume":"63","author":"Golden","year":"2002","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/da.22680-BIB0034|da22680-cit-0034","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/ajp.156.2.169","article-title":"Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome","volume":"156","author":"Gurrera","year":"1999","journal-title":"The American Journal of Psychiatry"},{"issue":"07","key":"10.1002\/da.22680-BIB0036|da22680-cit-0036","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4088\/JCP.11m07470","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/da.22680-BIB0037|da22680-cit-0037","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0269881108100254","article-title":"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder","volume":"24","author":"Hewett","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1002\/da.22680-BIB0038|da22680-cit-0038","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0269881108089602","article-title":"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","volume":"23","author":"Hewett","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"8","key":"10.1002\/da.22680-BIB0039|da22680-cit-0039","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0269881109106953","article-title":"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","volume":"24","author":"Hewett","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1002\/da.22680-BIB0040|da22680-cit-0040","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.4088\/JCP.14r09758","article-title":"Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: A meta-analysis","volume":"77","author":"Issari","year":"2016","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/da.22680-BIB0041|da22680-cit-0041","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1176\/appi.ajp.2015.15030331","article-title":"Systematic review and meta-analysis: Dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder","volume":"173","author":"Jakubovski","year":"2016","journal-title":"The American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/da.22680-BIB0042|da22680-cit-0042","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper","year":"2005","journal-title":"The British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/da.22680-BIB0043|da22680-cit-0043","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0b013e32831d7980","article-title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebo-controlled 8-week trial","volume":"24","author":"Kasper","year":"2009","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/da.22680-BIB0044|da22680-cit-0044","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/da.22680-BIB0045|da22680-cit-0045","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4088\/JCP.v58n0402","article-title":"A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients","volume":"58","author":"Kiev","year":"1997","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"11-12","key":"10.1002\/da.22680-BIB0046|da22680-cit-0046","first-page":"10","article-title":"Improvement of antidepressant-induced sweating with as-required benztropine","volume":"10","author":"Kolli","year":"2013","journal-title":"Innovations in Clinical Neuroscience"},{"issue":"02","key":"10.1002\/da.22680-BIB0047|da22680-cit-0047","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4088\/PCC.v09n0203","article-title":"Efficacy of duloxetine for the treatment of generalized anxiety disorder","volume":"09","author":"Koponen","year":"2007","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/da.22680-BIB0048|da22680-cit-0048","doi-asserted-by":"crossref","first-page":"P51","DOI":"10.1016\/j.jaad.2003.10.202","article-title":"Validity and reliability of the hyperhidrosis disease severity scale (HDSS)","volume":"50","author":"Kowalski","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/da.22680-BIB0049|da22680-cit-0049","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","article-title":"Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study","volume":"19","author":"Lader","year":"2004","journal-title":"Depression and Anxiety"},{"issue":"2","key":"10.1002\/da.22680-BIB0050|da22680-cit-0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1002\/da.22680-BIB0051|da22680-cit-0051","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0149-7634(85)90005-3","article-title":"Dopamine and thermoregulation: An evaluation with special reference to dopaminergic pathways","volume":"9","author":"Lee","year":"1985","journal-title":"Neuroscience Biobehavioral Reviews"},{"issue":"495","key":"10.1002\/da.22680-BIB0052|da22680-cit-0052","first-page":"772","article-title":"A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care","volume":"53","author":"Lenox-Smith","year":"2003","journal-title":"The British Journal of General Practice"},{"issue":"2","key":"10.1002\/da.22680-BIB0053|da22680-cit-0053","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v65n0213","article-title":"Controlled-release paroxetine in the treatment of patients with social anxiety disorder","volume":"65","author":"Lepola","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/da.22680-BIB0054|da22680-cit-0054","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004850-200307000-00003","article-title":"Escitalopram (10-20 mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"18","author":"Lepola","year":"2003","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/da.22680-BIB0055|da22680-cit-0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4088\/JCP.08m04238","article-title":"A Double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder","volume":"70","author":"Liebowitz","year":"2009","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/da.22680-BIB0056|da22680-cit-0056","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder","volume":"64","author":"Liebowitz","year":"2003","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/da.22680-BIB0057|da22680-cit-0057","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","article-title":"Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder","volume":"62","author":"Liebowitz","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"02","key":"10.1002\/da.22680-BIB0058|da22680-cit-0058","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","article-title":"A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder","volume":"66","author":"Liebowitz","year":"2005","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/da.22680-BIB0059|da22680-cit-0059","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1185\/03007990802161923","article-title":"Efficacy, safety, and tolerability of desvenlafaxine 50 mg\/day and 100 mg\/day in outpatients with major depressive disorder","volume":"24","author":"Liebowitz","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/da.22680-BIB0060|da22680-cit-0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","article-title":"A Randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder","volume":"63","author":"Liebowitz","year":"2002","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/da.22680-BIB0061|da22680-cit-0061","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-13-94","article-title":"A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg\/day in adult outpatients with major depressive disorder","volume":"13","author":"Liebowitz","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"5 Pt 2","key":"10.1002\/da.22680-BIB0062|da22680-cit-0062","first-page":"R1260","article-title":"Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function","volume":"274","author":"Lin","year":"1998","journal-title":"American Journal of Physiologl"},{"issue":"6","key":"10.1002\/da.22680-BIB0063|da22680-cit-0063","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JCP.0b013e31818d6b67","article-title":"Antidepressant-induced sweating alleviated by aripiprazole","volume":"28","author":"Lu","year":"2008","journal-title":"Journal of Clinical Psychopharmacol"},{"issue":"2","key":"10.1002\/da.22680-BIB0064|da22680-cit-0064","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/JCP.0b013e31828567f2","article-title":"Glycopyrrolate for antidepressant-associated excessive sweating","volume":"33","author":"Mago","year":"2013","journal-title":"Journal of Clinical Psychopharmacol"},{"issue":"3","key":"10.1002\/da.22680-BIB0065|da22680-cit-0065","first-page":"186","article-title":"Antidepressant-induced excessive sweating: Clinical features and treatment with terazosin","volume":"25","author":"Mago","year":"2013","journal-title":"Annals of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/da.22680-BIB0066|da22680-cit-0066","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/da.22680-BIB0067|da22680-cit-0067","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2013","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/da.22680-BIB0068|da22680-cit-0068","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10\u2009mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"4","key":"10.1002\/da.22680-BIB0069|da22680-cit-0069","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1345\/aph.1E564","article-title":"Antidepressant-induced sweating","volume":"39","author":"Marcy","year":"2005","journal-title":"Annals of Pharmacotheraphy"},{"issue":"1","key":"10.1002\/da.22680-BIB0070|da22680-cit-0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1212\/WNL.46.1.231","article-title":"[123I] beta-CIT\/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease","volume":"46","author":"Marek","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/da.22680-BIB0071|da22680-cit-0071","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00004714-200204000-00008","article-title":"Specific side effects of long-term imipramine management of panic disorder","volume":"22","author":"Mavissakalian","year":"2002","journal-title":"Journal of Clinical Psychopharmacol"},{"issue":"2","key":"10.1002\/da.22680-BIB0072|da22680-cit-0072","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1520-6394(1999)9:2<54::AID-DA2>3.0.CO;2-T","article-title":"Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia","volume":"9","author":"Mendels","year":"1999","journal-title":"Depression and Anxiety"},{"issue":"2","key":"10.1002\/da.22680-BIB0073|da22680-cit-0073","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder","volume":"16","author":"Montgomery","year":"2001","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/da.22680-BIB0074|da22680-cit-0074","unstructured":"National Guideline, C. 2010 https:\/\/www.guideline.gov\/summaries\/summary\/24158\/Practice-guideline-for-the-treatment-of-patients-with-major-depressive-disorder-third-edition"},{"issue":"02","key":"10.1002\/da.22680-BIB0075|da22680-cit-0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S0033291708003401","article-title":"Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: Examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial","volume":"39","author":"Nicolini","year":"2008","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/da.22680-BIB0076|da22680-cit-0076","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","article-title":"Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, a non-inferiority study","volume":"23","author":"Nierenberg","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/da.22680-BIB0077|da22680-cit-0077","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00004850-200411000-00003","article-title":"Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study","volume":"19","author":"Nimatoudis","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/da.22680-BIB0078|da22680-cit-0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder","volume":"24","author":"Pollack","year":"2006","journal-title":"Depression and Anxiety"},{"issue":"4","key":"10.1002\/da.22680-BIB0079|da22680-cit-0079","first-page":"667","article-title":"Venlafaxine for panic disorder: Results from a double-blind, placebo-controlled study","volume":"32","author":"Pollack","year":"1996","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl6","key":"10.1002\/da.22680-BIB0080|da22680-cit-0080","first-page":"12","article-title":"Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine","volume":"56","author":"Preskorn","year":"1995","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"Suppl B","key":"10.1002\/da.22680-BIB0081|da22680-cit-0081","first-page":"18","article-title":"Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression","volume":"51","author":"Reimherr","year":"1990","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/da.22680-BIB0082|da22680-cit-0082","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0149-2918(98)80060-X","article-title":"A multicenter evaluation of the efficacy and safety of 150 and 300 mg\/d sustained-release bupropion tablets versus placebo in depressed outpatients","volume":"20","author":"Reimherr","year":"1998","journal-title":"Clinical Therapeutics"},{"issue":"16","key":"10.1002\/da.22680-BIB0083|da22680-cit-0083","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1517\/14656566.2011.618496","article-title":"Pharmacological treatment of generalized anxiety disorder","volume":"12","author":"Reinhold","year":"2011","journal-title":"Expert Opinion of Pharmacotheraphy"},{"issue":"S350","key":"10.1002\/da.22680-BIB0084|da22680-cit-0084","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0447.1989.tb07188.x","article-title":"A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients","volume":"80","author":"Rickels","year":"1989","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/da.22680-BIB0085|da22680-cit-0085","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","article-title":"A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder","volume":"24","author":"Rickels","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/da.22680-BIB0086|da22680-cit-0086","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","article-title":"Paroxetine treatment of generalized anxiety disorder: A double-blind, placebo-controlled study","volume":"160","author":"Rickels","year":"2003","journal-title":"The American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/da.22680-BIB0087|da22680-cit-0087","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/jnnp.67.6.737","article-title":"Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease","volume":"67","author":"Rinne","year":"1999","journal-title":"Journal of Neurology, Neurosurgery, Psychiatry"},{"issue":"2-3","key":"10.1002\/da.22680-BIB0088|da22680-cit-0088","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0165-0327(99)00067-1","article-title":"A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression","volume":"56","author":"Rudolph","year":"1999","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/da.22680-BIB0089|da22680-cit-0089","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.v60n0105","article-title":"Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety","volume":"60","author":"Silverstone","year":"1999","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/da.22680-BIB0090|da22680-cit-0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4088\/JCP.v62n07a04","article-title":"Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder","volume":"62","author":"Silverstone","year":"2001","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/da.22680-BIB0091|da22680-cit-0091","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/depr.3050030407","article-title":"Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder","volume":"3","author":"Sramek","year":"1995","journal-title":"Depression"},{"issue":"04","key":"10.1002\/da.22680-BIB0092|da22680-cit-0092","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder","volume":"75","author":"Stein","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/da.22680-BIB0093|da22680-cit-0093","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive-compulsive disorder: A randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"8","key":"10.1002\/da.22680-BIB0094|da22680-cit-0094","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder)","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/da.22680-BIB0095|da22680-cit-0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","article-title":"Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial","volume":"177","author":"Stein","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/da.22680-BIB0096|da22680-cit-0096","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12888-015-0391-3","article-title":"Escitalopram in the prevention of posttraumatic stress disorder: A pilot randomized controlled trial","volume":"15","author":"Suliman","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"12","key":"10.1002\/da.22680-BIB0097|da22680-cit-0097","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/mds.10586","article-title":"Sweating dysfunction in Parkinson's disease","volume":"18","author":"Swinn","year":"2003","journal-title":"Movement Disorders"},{"issue":"12 Suppl 15","key":"10.1002\/da.22680-BIB0098|da22680-cit-0098","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1017\/S1092852900015212","article-title":"Preventing relapse and recurrence of depression: A brief review of therapeutic options","volume":"11","author":"Thase","year":"2006","journal-title":"CNS Spectrums"},{"key":"10.1002\/da.22680-BIB0099|da22680-cit-0099","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100 mg\/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","volume":"31","author":"Tourian","year":"2009","journal-title":"Clinical Therapeutics"},{"issue":"10","key":"10.1002\/da.22680-BIB0100|da22680-cit-0100","first-page":"1245","article-title":"Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis","volume":"159","author":"Trindade","year":"1998","journal-title":"Canadian Medical Association Journal"},{"issue":"10","key":"10.1002\/da.22680-BIB0101|da22680-cit-0101","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4088\/JCP.v62n1005","article-title":"Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients","volume":"62","author":"Trivedi","year":"2001","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/da.22680-BIB0102|da22680-cit-0102","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","article-title":"Sertraline treatment of generalized social phobia: A 20-Week, double-blind, placebo-controlled study","volume":"158","author":"Ameringen","year":"2001","journal-title":"The American Journal of Psychiatry"},{"issue":"6 Suppl Depress","key":"10.1002\/da.22680-BIB0103|da22680-cit-0103","first-page":"25","article-title":"An overview of SSRI and SNRI therapies for depression","volume":"13","author":"Weilburg","year":"2004","journal-title":"Managed Care"},{"issue":"26","key":"10.1002\/da.22680-BIB0104|da22680-cit-0104","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1056\/NEJM200012283432607","article-title":"Managing depression in medical outpatients","volume":"343","author":"Whooley","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/da.22680-BIB0105|da22680-cit-0105","first-page":"3260","article-title":"Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China","volume":"124","author":"Wu","year":"2011","journal-title":"Chinese Medical Journal (Engl)"},{"key":"10.1002\/da.22680-BIB0106|da22680-cit-0106","unstructured":"Wyeth Pfizer 2011"},{"issue":"4","key":"10.1002\/da.22680-BIB0107|da22680-cit-0107","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","article-title":"Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine study investigators","volume":"169","author":"Zohar","year":"1996","journal-title":"The British Journal of Psychiatry"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.22680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/da.22680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T08:04:55Z","timestamp":1671523495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.22680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,7]]},"references-count":107,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1002\/da.22680","archive":["Portico"],"relation":{},"ISSN":["1091-4269"],"issn-type":[{"value":"1091-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,7]]}}}